Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
For 2024, the company expects sales of $793 million – $798 million compared to prior guidance of $788 million – $798 million and a consensus of $796.09 million.BofA Securities has upgraded Inspire Medical Systems, Inc. (NYSE:INSP) and says the company now falls in the profitable growth category.
美银证券已经对Inspire Medical Systems, Inc.（纽约证券交易所代码：INSP）进行了升级，并表示该公司现在属于盈利增长类别。
Inspire Medical is expected to give its 2025 revenue guidance in early January, likely alongside its fourth-quarter results.
Inspire Medical预计将在1月初公布其2025年的收入指导，可能还会公布其第四季度业绩。
The company has already stated that it is comfortable with the Street's consensus of $950 million in revenue for 2025.
该公司已经表示，它对华尔街共识的2025年收入为9.5亿美元感到满意。
For 2024, the company expects sales of $793 million – $798 million compared to prior guidance of $788 million – $798 million and a consensus of $796.09 million.
该公司预计2024年的销售额为7.93亿美元至7.98亿美元，而之前的预期为7.88亿美元至7.98亿美元，共识为7.96亿美元。
BofA has upgraded the stock from Neutral to Buy with a price target of $255, up from $220.
美国银行已将该股从中性上调至买入，目标股价为255美元，从220美元上涨。
Inspire Medical's outlook for 2025 is based on plans to hire more staff, open new centers, increase direct-to-consumer advertising, expand treatment indications, and boost capacity.
Inspire Medical对2025年的展望基于雇用更多员工、开设新中心、增加直接面向消费者的广告、扩大治疗适应症和提高产能的计划。
Also Read: FDA Labels Inspire Medical's Sleep Apnea Nerve Stimulator Recall As Most Serious
另请阅读：美国食品药品管理局将Inspire Medical的睡眠呼吸暂停神经刺激器召回标记为最严重
The Inspire V system, expected to make a bigger impact in the second half of 2025 after the Inspire IV to V transition, could make the procedure easier and more accessible to more doctors, including general surgeons, ENTs, and neurosurgeons.
Inspire V系统预计将在Inspire IV向V过渡后的2025年下半年产生更大的影响，它可以使包括普通外科医生、耳鼻喉科医生和神经外科医生在内的更多医生更容易接受手术。
In August, the FDA approved the Inspire V therapy system, which includes the next-generation neurostimulator and the associated Bluetooth patient remote and physician programmer.
8月，美国食品药品管理局批准了Inspire V治疗系统，其中包括下一代神经刺激器以及相关的蓝牙患者遥控器和医生编程器。
The company targets a soft launch in late 2024 and a full launch in 2025
该公司的目标是在2024年底试推出，在2025年全面推出
One major advantage of Inspire V is that it simplifies the procedure by eliminating the need to place the sensing lead, which was a more complicated part of the process.
Inspire V的一个主要优势是，它无需放置传感导线，从而简化了程序，而传感导线是过程中更为复杂的一部分。
The analyst writes, "There are limited smid cap profitable growth stocks with a new product story in 2025 and INSP screens attractive as we look for top smid cap ideas in 2025. INSP seems on the path towards double digit margins which is when valuations tend to inflect and strategic interest increases."
这位分析师写道：“中型股盈利成长型股票有限，2025年将推出新的产品故事，而INSP的屏幕很有吸引力，因为我们在2025年寻找最佳的中型股创意。INSP似乎走上了通往两位数利润率的道路，而这时估值往往会发生变化，战略利益会增加。”
Price Action: INSP stock is up 4.90% at $184.67 at last check Wednesday.
价格走势：周三最后一次检查时，INSP股价上涨4.90％，至184.67美元。
Photo by Ground Picture on Shutterstock
照片由 Shutterstock 上的 Ground Pict
- What's Going On With Lifeway Stock After Rejecting Revised Acquisition Offer From Danone?
- 拒绝达能修订后的收购要约后，Lifeway的股票怎么了？
